Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer – Newswise (press release)
|
Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer
Newswise (press release) Newswise — New Brunswick, N.J., August 16, 2017 – The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in … |
